Observational Prospective Study to Assess the Safety and Effectiveness Profile of Beltavac® Polymerized With Alternaria Alternata
Phase of Trial: Phase IV
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Alternaria allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Probelte Pharma
- 24 Apr 2019 Planned End Date changed from 30 May 2019 to 30 Dec 2020.
- 24 Apr 2019 Planned primary completion date changed from 30 Apr 2019 to 30 Nov 2020.
- 03 Aug 2018 New trial record